The immunopathogenesis of Crohn's disease: a three-stage model

Current Opinion in Immunology

Volumn 21, Issue 5, 2009, Pages 506-513

  Sewell, Gavin W ^a   Marks, Daniel JB ^a   Segal, Anthony W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; CROHN DISEASE; DISEASE MODEL; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GRANULOMATOUS INFLAMMATION; HEREDITY; HERITABILITY; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; NONHUMAN; PHENOTYPE; REVIEW; SYMPTOM;

ANIMALS; BACTERIAL INFECTIONS; CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; MODELS, IMMUNOLOGICAL;

EID: 70349756909     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2009.06.003     Document Type: Review

References (67)

1. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 347 (2002) 417-429
2. Korzenik J.R. Past and current theories of etiology of IBD: toothpaste, worms, and refrigerators. J Clin Gastroenterol 39 (2005) S59-S65
3. Halme L., Paavola-Sakki P., Turunen U., Lappalainen M., Farkkila M., and Kontula K. Family and twin studies in inflammatory bowel disease. World J Gastroenterol 12 (2006) 3668-3672
4. Barrett J.C., Hansoul S., Nicolae D.L., Cho J.H., Duerr R.H., Rioux J.D., Brant S.R., Silverberg M.S., Taylor K.D., Barmada M.M., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40 (2008) 955-962. A meta-analysis of three GWA studies for CD, which resulted in the identification of over 20 new susceptibility loci, and verification of genes previously identified as associated with CD.
5. Hugot J.P., Zaccaria I., Cavanaugh J., Yang H., Vermeire S., Lappalainen M., Schreiber S., Annese V., Jewell D.P., Fowler E.V., et al. Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol 102 (2007) 1259-1267
6. Cuthbert A.P., Fisher S.A., Mirza M.M., King K., Hampe J., Croucher P.J., Mascheretti S., Sanderson J., Forbes A., Mansfield J., et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 122 (2002) 867-874
7. Weedon M.N., Lango H., Lindgren C.M., Wallace C., Evans D.M., Mangino M., Freathy R.M., Perry J.R., Stevens S., Hall A.S., et al. Genome-wide association analysis identifies 20 loci that influence adult height. Nat Genet 40 (2008) 575-583
8. Lettre G., Jackson A.U., Gieger C., Schumacher F.R., Berndt S.I., Sanna S., Eyheramendy S., Voight B.F., Butler J.L., Guiducci C., et al. Identification of ten loci associated with height highlights new biological pathways in human growth. Nat Genet 40 (2008) 584-591
9. Gudbjartsson D.F., Walters G.B., Thorleifsson G., Stefansson H., Halldorsson B.V., Zusmanovich P., Sulem P., Thorlacius S., Gylfason A., Steinberg S., et al. Many sequence variants affecting diversity of adult human height. Nat Genet 40 (2008) 609-615
10. Maher B. Personal genomes: the case of the missing heritability. Nature 456 (2008) 18-21. This Nature news feature discusses the concept of 'missing heritability' in the light of recent 'disease susceptibility genes' identified by GWA studies.
11. Wirtz S., and Neurath M.F. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 59 (2007) 1073-1083
12. Hoffmann J.C., Pawlowski N.N., Kuhl A.A., Hohne W., and Zeitz M. Animal models of inflammatory bowel disease: an overview. Pathobiology 70 (2002) 121-130
13. Pauleau A.L., and Murray P.J. Role of NOD2 in the response of macrophages to toll-like receptor agonists. Mol Cell Biol 23 (2003) 7531-7539
14. Saitoh T., Fujita N., Jang M.H., Uematsu S., Yang B.G., Satoh T., Omori H., Noda T., Yamamoto N., Komatsu M., et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456 (2008) 264-268
15. Cadwell K., Liu J.Y., Brown S.L., Miyoshi H., Loh J., Lennerz J.K., Kishi C., Kc W., Carrero J.A., Hunt S., et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456 (2008) 259-263
16. Edwards C.M., George B.D., Jewell D.P., Warren B.F., Mortensen N.J., and Kettlewell M.G. Role of a defunctioning stoma in the management of large bowel Crohn's disease. Br J Surg 87 (2000) 1063-1066
17. Winslet M.C., Allan A., Poxon V., Youngs D., and Keighley M.R. Faecal diversion for Crohn's colitis: a model to study the role of the faecal stream in the inflammatory process. Gut 35 (1994) 236-242
18. D'Haens G.R., Geboes K., Peeters M., Baert F., Penninckx F., and Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114 (1998) 262-267
19. Berkes J., Viswanathan V.K., Savkovic S.D., and Hecht G. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 52 (2003) 439-451
20. McGuckin M.A., Eri R., Simms L.A., Florin T.H., and Radford-Smith G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 15 (2009) 100-113
21. Olaison G., Leandersson P., Sjodahl R., and Tagesson C. Intestinal permeability to polyethyleneglycol 600 in Crohn's disease. Peroperative determination in a defined segment of the small intestine. Gut 29 (1988) 196-199
22. Ukabam S.O., Clamp J.R., and Cooper B.T. Abnormal small intestinal permeability to sugars in patients with Crohn's disease of the terminal ileum and colon. Digestion 27 (1983) 70-74
23. Bjarnason I., O'Morain C., Levi A.J., and Peters T.J. Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 85 (1983) 318-322
24. Casellas F., Aguade S., Soriano B., Accarino A., Molero J., and Guarner L. Intestinal permeability to 99mTc-diethylenetriaminopentaacetic acid in inflammatory bowel disease. Am J Gastroenterol 81 (1986) 767-770
25. Peeters M., Ghoos Y., Maes B., Hiele M., Geboes K., Vantrappen G., and Rutgeerts P. Increased permeability of macroscopically normal small bowel in Crohn's disease. Dig Dis Sci 39 (1994) 2170-2176
26. Wyatt J., Vogelsang H., Hubl W., Waldhoer T., and Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 341 (1993) 1437-1439
27. Hollander D., Vadheim C.M., Brettholz E., Petersen G.M., Delahunty T., and Rotter J.I. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 105 (1986) 883-885
28. Breslin N.P., Nash C., Hilsden R.J., Hershfield N.B., Price L.M., Meddings J.B., and Sutherland L.R. Intestinal permeability is increased in a proportion of spouses of patients with Crohn's disease. Am J Gastroenterol 96 (2001) 2934-2938
29. Moehle C., Ackermann N., Langmann T., Aslanidis C., Kel A., Kel-Margoulis O., Schmitz-Madry A., Zahn A., Stremmel W., and Schmitz G. Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med 84 (2006) 1055-1066
30. Libioulle C., Louis E., Hansoul S., Sandor C., Farnir F., Franchimont D., Vermeire S., Dewit O., de Vos M., Dixon A., et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet 3 (2007) e58
31. Kabashima K., Saji T., Murata T., Nagamachi M., Matsuoka T., Segi E., Tsuboi K., Sugimoto Y., Kobayashi T., Miyachi Y., et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 109 (2002) 883-893
32. Hermiston M.L., and Gordon J.I. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 270 (1995) 1203-1207
33. Heazlewood C.K., Cook M.C., Eri R., Price G.R., Tauro S.B., Taupin D., Thornton D.J., Png C.W., Crockford T.L., Cornall R.J., et al. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med 5 (2008) e54
34. Olson T.S., Reuter B.K., Scott K.G., Morris M.A., Wang X.M., Hancock L.N., Burcin T.L., Cohn S.M., Ernst P.B., Cominelli F., et al. The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med 203 (2006) 541-552
35. Segal A.W., and Loewi G. Neutrophil dysfunction in Crohn's disease. Lancet 2 (1976) 219-221. The first demonstration of impaired acute inflammation in patients with CD, using a skin window technique.
36. Marks D.J., Harbord M.W., MacAllister R., Rahman F.Z., Young J., Al Lazikani B., Lees W., Novelli M., Bloom S., and Segal A.W. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 367 (2006) 668-678. In this study, impaired recruitment of neutrophils to both skin windows and sites of trauma in the bowel, was demonstrated in CD patients. This was related to reduced concentrations of pro-inflammatory mediators at these sites, including IL-8 and IL-1β, with associated cellular defects identified at the level of the macrophage. The pathophysiological relevance of these findings was illustrated by demonstrating grossly attenuated acute inflammatory responses to bacteria subcutaneously inoculated into CD patients.
37. Morain C.O., Segal A.A., Walker D., and Levi A.J. Abnormalities of neutrophil function do not cause the migration defect in Crohn's disease. Gut 22 (1981) 817-822
38. Medzhitov R. Origin and physiological roles of inflammation. Nature 454 (2008) 428-435
39. Smythies L.E., Maheshwari A., Clements R., Eckhoff D., Novak L., Vu H.L., Mosteller-Barnum L.M., Sellers M., and Smith P.D. Mucosal IL-8 and TGF-beta recruit blood monocytes: evidence for cross-talk between the lamina propria stroma and myeloid cells. J Leukoc Biol 80 (2006) 492-499
40. Marks D.J., Miyagi K., Rahman F.Z., Novelli M., Bloom S.L., and Segal A.W. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am J Gastroenterol 104 (2009) 117-124
41. + flux. Nature 416 (2002) 291-297
42. Rahman F.Z., Marks D.J., Hayee B.H., Smith A.M., Bloom S.L., and Segal A.W. Phagocyte dysfunction and inflammatory bowel disease. Inflamm Bowel Dis 14 (2008) 1443-1452
43. Korzenik J.R., and Dieckgraefe B.K. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease. Dig Dis Sci 45 (2000) 1121-1129
44. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
45. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., Almer S., Tysk C., O'Morain C.A., Gassull M., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
46. Li J., Moran T., Swanson E., Julian C., Harris J., Bonen D.K., Hedl M., Nicolae D.L., Abraham C., and Cho J.H. Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet 13 (2004) 1715-1725
47. Wehkamp J., Harder J., Weichenthal M., Schwab M., Schaffeler E., Schlee M., Herrlinger K.R., Stallmach A., Noack F., Fritz P., et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 53 (2004) 1658-1664
48. Noguchi E., Homma Y., Kang X., Netea M.G., and Ma X. A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol 10 (2009) 471-479
49. Rioux J.D., Xavier R.J., Taylor K.D., Silverberg M.S., Goyette P., Huett A., Green T., Kuballa P., Barmada M.M., Datta L.W., et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 39 (2007) 596-604. This GWA study confirmed ATG16L1 as a CD susceptibility gene, and identified a functional role for the ATG16L1 protein in autophagy of intracellular bacteria.
50. Hampe J., Franke A., Rosenstiel P., Till A., Teuber M., Huse K., Albrecht M., Mayr G., De L.V., Briggs J., et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 39 (2007) 207-211. A GWA study of over 1000 individuals that led to the discovery of ATG16L1 as a CD susceptibility gene.
51. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared, controls. Nature 447 (2007) 661-678
52. Singh S.B., Davis A.S., Taylor G.A., and Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 313 (2006) 1438-1441
53. Kuballa P., Huett A., Rioux J.D., Daly M.J., and Xavier R.J. Impaired autophagy of an intracellular pathogen induced by a Crohn's disease associated ATG16L1 variant. PLoS ONE 3 (2008) e3391
54. Welte T., Zhang S.S., Wang T., Zhang Z., Hesslein D.G., Yin Z., Kano A., Iwamoto Y., Li E., Craft J.E., et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A 100 (2003) 1879-1884
55. Porter C.K., Tribble D.R., Aliaga P.A., Halvorson H.A., and Riddle M.S. Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology 135 (2008) 781-786
56. Kyle J. Urinary complications of Crohn's disease. World J Surg 4 (1980) 153-160
57. Neish A.S. Microbes in gastrointestinal health and disease. Gastroenterology 136 (2009) 65-80
58. Marks D.J., Mitchison N.A., Segal A.W., and Sieper J. Can unresolved infection precipitate autoimmune disease?. Curr Top Microbiol Immunol 305 (2006) 105-125
59. Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S., Daly M.J., Steinhart A.H., Abraham C., Regueiro M., Griffiths A., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006) 1461-1463
60. Iwakura Y., and Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 116 (2006) 1218-1222
61. Izcue A., Hue S., Buonocore S., Arancibia-Carcamo C.V., Ahern P.P., Iwakura Y., Maloy K.J., and Powrie F. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 28 (2008) 559-570
62. Mizoguchi A., Ogawa A., Takedatsu H., Sugimoto K., Shimomura Y., Shirane K., Nagahama K., Nagaishi T., Mizoguchi E., Blumberg R.S., et al. Dependence of intestinal granuloma formation on unique myeloid DC-like cells. J Clin Invest 117 (2007) 605-615
63. Fisher S.A., Tremelling M., Anderson C.A., Gwilliam R., Bumpstead S., Prescott N.J., Nimmo E.R., Massey D., Berzuini C., Johnson C., et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 40 (2008) 710-712
64. ten Hove T., van Montfrans C., Peppelenbosch M.P., and van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50 (2002) 206-211
65. Ricciardelli I., Lindley K.J., Londei M., and Quaratino S. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. Immunology 125 (2008) 178-183
66. Gonvers J.J., Juillerat P., Mottet C., Felley C., Burnand B., Vader J.P., Michetti P., and Froehlich F. Maintenance of remission in Crohn's disease. Digestion 71 (2005) 41-48
67. Smith AM, Rahman FZ, Hayee BH, Graham SJ, Marks DJ, Sewell GW, Palmer CD, Wilde J, Foxwell BM, Gloger IS et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med, in press. In this study, impaired clearance of bacteria was demonstrated in CD patients, which was related to defects in the innate immune system. Macrophages cultured from CD patients were found to secrete deficient levels of pro-inflammatory cytokines in response to stimulation with heat killed E. coli. This was shown to arise from abnormal routing of cytokines to the lysosomal compartments in these cells, which results in degradation rather than release through the normal secretory pathway.